Ergoferon, tablets 20 pcs

The spectrum of Ergoferon pharmacological activity includes antiviral, immunomodulatory, antihistamine, anti-inflammatory.

The effectiveness of Ergoferon components for viral infectious diseases has been experimentally and clinically proved: influenza A and influenza B, acute respiratory viral infections (caused by parainfluenza viruses, adenoviruses, respiratory syncytial viruses, coronaviruses), herpesvirus infections (labial herpes, ophthalmoherpes, genital herpes, herpes zoster, Chicken pox, infectious mononucleosis), acute intestinal infections of viral etiology (caused by caliciviruses, coronaviruses, rotaviruses, enteroviruses), enteroviral and meningococcal meningitis, hemorrhagic fever with renal syndrome, encephalitis.

Ergoferon is used in combination therapy of bacterial infections (pseudotuberculosis, whooping cough, yersiniosis, pneumonia of various etiologies including atypical pathogens (M. pneumoniae, C. Pneumoniae, Legionella spp), is used for prevention of bacterial complications of viral infections, prevents the development of superinfections. The usage of Ergoferon during pre- and post-vaccination period increases the effectiveness of vaccination, provides non-specific prophylaxis of ARVI and flu in the period of post-vaccination immunity establishment. Ergoferon possesses prophylactic effectiveness against acute respiratory viral infections of non-flu etiology, prevents the development of intercurrent diseases in postvaccination period.

Components of Ergoferon possess the same mechanism of action as activation of functional activity of CD4 receptor, receptors to interferon gamma (IFN-γ) and histamine, correspondingly accompanied by pronounced immunotropic action.

It was experimentally proved that antibodies to interferon gamma:
increase expression of IFN-γ, IFN α/β and associated interleukins (IL-2, IL-4, IL-10 and others).), improve ligand-receptor interaction of IFN, restore cytokine status; normalize the concentration and functional activity of natural antibodies to IFN-γ, which is an important factor in the natural antiviral tolerance of the body; stimulate interferon-dependent biological processes: induction of expression of antigens of the main histocompatibility complex of types I, II and Fc-receptors, monocyte activation, stimulation of functional activity of NK-cells, regulation of immunoglobulin synthesis, activating mixed Th1 and Th2 immune response.

Antibodies to CD4, being probably allosteric modulators of the receptor, regulate functional activity of CD4 receptor that results in increase of functional activity of CD4 lymphocytes, normalization of immunoregulatory index CD4/CD8 as well as subpopulation structure of immunocompetent cells (CD3, CD4, CD8, CD16, CD20).

. Antibodies to histamine modify histamine-dependent activation of peripheral and central H1-receptors, thus reducing tone of bronchial smooth muscle and capillary permeability that results in reduction of duration and severity of rhinorrhea, nasal mucous membrane edema, cough and sneezing,
Allergic reactions accompanying infectious process decrease due to suppression of histamine release from mast cells and basophils, leukotrienes production, adhesion molecules synthesis, decrease of eosinophils chemotaxis and platelet aggregation in reactions to contact with allergen.

Combined use of components of Ergoferon complex preparation is accompanied by enhanced antiviral activity of its components.

Indications

Treatment of influenza and acute respiratory viral infections (ARVI) in adults and children over 6 months of age.
Treatment of acute intestinal infections of viral etiology (ACVI) in adults and children over 6 months of age.
Nonspecific prevention of COVID-19 during the period of vaccination between the introduction of the first and second components of the vaccine against a new coronavirus infection in adults.

Pharmacological effect

Pharmacotherapeutic group

Antiviral and immunostimulating agent.

ATX code

L03AX.

Pharmacological properties

Pharmacodynamics

The spectrum of pharmacological activity of the drug Ergoferon® includes antiviral, immunomodulatory, antihistamine, and anti-inflammatory.

The components included in the drug have a single mechanism of action in the form of increasing the functional activity of the CD4 receptor, receptors for interferon gamma (IFNγ) and histamine, respectively, which is accompanied by a pronounced immunotropic effect.

It has been experimentally proven that antibodies to interferon gamma: increase the expression of IFNγ, IFNa/β, as well as interleukins associated with them (IL-2, IL-4, IL-10, etc.), improve the ligand-receptor interaction of IFN, restore cytokine status; normalize the concentration and functional activity of natural antibodies to IFNγ, which are an important factor in the body’s natural antiviral tolerance; stimulate interferon-dependent biological processes: induction of expression of major histocompatibility complex type I, II antigens and Fc receptors, activation of monocytes, stimulation of the functional activity of NK cells, regulation of immunoglobulin synthesis, activating a mixed Th1 and Th2 immune response.

Antibodies to CD4, probably being allosteric modulators of this receptor, regulate the functional activity of the CD4 receptor, which leads to an increase in the functional activity of CD4+ lymphocytes, normalization of the CD4+/CD8+ immunoregulatory index, as well as the subpopulation composition of immunocompetent cells (CD3+, CD4+, CD8+, CD16+, CD20+).

Antibodies to histamine modify histamine-dependent activation of peripheral and central H1 receptors and, thus, reduce the tone of bronchial smooth muscles, reduce capillary permeability, which leads to a reduction in the duration and severity of rhinorrhea, swelling of the nasal mucosa, coughing and sneezing, as well as a decrease in the severity of allergic reactions accompanying the infectious process by suppressing the release histamine from mast cells and basophils, production of leukotrienes, synthesis of adhesion molecules, reduction of eosinophil chemotaxis and platelet aggregation in reactions to contact with an allergen.

The combined use of the components of a complex drug is accompanied by an increase in the antiviral activity of its components.

During the ongoing experimental and clinical studies, therapeutic efficacy was established against influenza viruses, parainfluenza, rhinovirus, metapneumovirus, seasonal strains of coronaviruses, bocavirus, respiratory syncytial virus, respiratory and intestinal strains of adenovirus, rotaviruses, noroviruses, astroviruses, as well as nonspecific preventive efficacy against SARS-CoV-2. A clinical study found a 3-fold reduction in the risk of COVID-19 disease during the vaccination period between the introduction of components I and II of the Gam-COVID-Vac vaccine against the background of prophylactic administration of the drug Ergoferon®.

Pharmacokinetics

The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, gas chromatography-mass spectrometry) does not allow assessing the content of active ingredients of the drug Ergoferon® in biological fluids, organs and tissues, which makes it technically impossible to study pharmacokinetics.

Special instructions

The drug contains lactose monohydrate, and therefore is not recommended for use in patients with congenital galactosemia, glucose malabsorption syndrome, or congenital lactase deficiency.

Impact on the ability to drive vehicles and machinery
Ergoferon® does not affect the ability to drive vehicles and other potentially dangerous mechanisms.

Active ingredient

Antibodies

Composition

Active ingredients:

affinity purified antibodies to human interferon gamma – 10,000 EMD*,

affinity purified antibodies to histamine – 10,000 EMD*,

affinity purified antibodies to CD4 – 10,000 EMD*.

Excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate.

* EMD – units of modifying action.

Pregnancy

The safety of Ergoferon® in pregnant women has not been studied.
During pregnancy and lactation, the drug is used only if the expected benefit to the mother outweighs the potential risk to the fetus and child. The benefit-risk ratio is determined by the attending physician.

Contraindications

Increased individual sensitivity to the components of the drug.
Lactase deficiency, hereditary galactose intolerance, glucose-galactose malabsorption.
Children up to 6 months of age – for the treatment of influenza, ARVI and ARVI.
Children under 18 years of age – for nonspecific prevention of COVID-19 during the period of vaccination between the introduction of the first and second components of the vaccine against the new coronavirus infection.

Side Effects

Individual hypersensitivity reactions to the components of the drug are possible. If you experience any unwanted reactions listed in the instructions or they get worse, or you notice any other unwanted reactions not listed in the instructions, tell your doctor.

Interaction

No cases of incompatibility with other drugs have been reported to date.

Overdose

In case of overdose, dyspepsia may occur due to the excipients included in the drug. Treatment consists of discontinuing the drug and prescribing symptomatic therapy, for example, oral rehydration.

Short product description

Ergoferon – has several therapeutic effects.

The first, most important thing is the antiviral effect.

The second equally important effect of the drug is immunomodulatory. The product mobilizes the body’s defenses for a more coordinated and rapid fight against infection, including through active recognition of the pathogen and an adequate immune response to its invasion. Thanks to its anti-inflammatory and antihistamine effects, Ergoferon helps reduce the severity and duration of swelling of the mucous membranes, bronchospasm and cough.

The drug Ergoferon is available in a convenient dosage form (lozenges) and can be used to treat influenza and ARVI in all family members – adults and children starting from 6 months of age.

Storage conditions

At a temperature not exceeding 25 °C.
Keep out of the reach of children.

Shelf life

3 years.

Do not use after expiration date.

Manufacturer

Materia Medica Holding, Russia